Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency

Jolles, Stephen 2013. Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency. ImmunoTargets and Therapy 2 , pp. 125-133. 10.2147/ITT.S31136

Full text not available from this repository.


Immunoglobulin (Ig)-replacement therapy represents the mainstay of treatment for patients with primary antibody deficiency and is administered either intravenously (IVIg) or subcutaneously (SCIg). While hyaluronidase has been used in clinical practice for over 50 years, the development of a high-purity recombinant form of this enzyme (recombinant human hyaluronidase PH20) has recently enabled the study of repeated and more prolonged use of hyaluronidase in facilitating the delivery of SC medicines. It has been used in a wide range of clinical settings to give antibiotics, local anesthetics, insulin, morphine, fluid replacement, and larger molecules, such as antibodies. Hyaluronidase has been used to help overcome the limitations on the maximum volume that can be delivered into the SC space by enabling dispersion of SCIg and its absorption into lymphatics. The rate of facilitated SCIg (fSCIg) infusion is equivalent to that of IVIg, and the volume administered at a single site can be greater than 700 mL, a huge increase over conventional SCIg, at 20–40 mL. The use of fSCIg avoids the higher incidence of systemic side effects of IVIg, and it has higher bioavailability than SCIg. Data on the long-term safety of this approach are currently lacking, as fSCIg has only recently become available. fSCIg may help several areas of patient management in primary antibody deficiency, and the extent to which it may be used in future will depend on long-term safety data and cost–benefit analysis.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Publisher: Dove Medical Press
ISSN: 2253-1556
Funders: N/A
Date of Acceptance: 10 August 2013
Last Modified: 04 Jan 2019 16:24

Actions (repository staff only)

Edit Item Edit Item